Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Protego Biopharma Inc. maintains 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 3 distinct examiners across 3 distinct art units. The busiest examiner, KUCHARCZK, JED A, is currently managing 1 pending office action.
The portfolio exhibits a high degree of fragmentation, as the 3 pending office actions are spread across 3 distinct examiners and 3 distinct art units. This means that every pending matter is being evaluated by a different individual in a different technical section of the patent office. KUCHARCZK, JED A, with 1 pending office action, is one of three examiners currently reviewing the company's work.
With 3 pending office actions in total, the company is actively engaged in the Biotechnology & Pharmaceuticals sector. The lack of overlap between the 3 distinct examiners and 3 distinct art units suggests that the company's intellectual property covers a variety of technical niches. Practitioners must be prepared for three separate prosecution tracks, as no two pending office actions share a common examiner or art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCHARCZK, JED A | 1 | 80.2% | +16.7% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18419081 | TRANSTHYRETIN STABILIZING COMPOUNDS | KUCHARCZK, JED A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18494596 | Spirocycle Containing Bicyclic Heteroaryl Compounds | ANDERSON, REBECCA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18419081 | TRANSTHYRETIN STABILIZING COMPOUNDS | KUCHARCZK, JED A | — |
| 18494601 | Spirocycle Containing Pyridine Compounds | KOSAR, ANDREW D | — |
| 18494596 | Spirocycle Containing Bicyclic Heteroaryl Compounds | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1625 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18419081 | TRANSTHYRETIN STABILIZING COMPOUNDS | KUCHARCZK, JED A | 1623 | §102DP | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18494601 | Spirocycle Containing Pyridine Compounds | KOSAR, ANDREW D | 1625 | §112DP | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18494596 | Spirocycle Containing Bicyclic Heteroaryl Compounds | ANDERSON, REBECCA L | 1626 | §102§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial